🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Gerald J. Dal Pan

Center for Drug Evaluation and Research

ORCID: 0000-0003-4874-5864

Pharmacology, Toxicology and PharmaceuticsMedicineMathematics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 9 papers. Top paper: “Special Applications of Pharmacoepidemiology”.

Special Applications of Pharmacoepidemiology

Textbook of Pharmacoepidemiology(2013)10.1002/9781118344828.ch22

N/A

0.330DataRank · unranked

8 citations

David Lee, Sumit R. Majumdar, Helene L. Lipton, Stephen B. Soumerai, Claudia Vellozzi +16 more

Prescription Drugs Subject to a Risk Evaluation and Mitigation Strategy: Patient Perspectives on Risk Communication and the Value of Educational Materials

Drug Safety(2025)10.1007/s40264-025-01636-4

N/A

0.104DataRank · unranked

1 citations

Carol Cosenza, Aaron S. Kesselheim, Gita A. Toyserkani, Kate Heinrich Oswell, Cynthia LaCivita +3 more

The US Food and Drug Administration, neurologists, and drug development and regulation

Neurology Clinical Practice(2015)10.1212/cpj.0000000000000153

N/A

0.104DataRank · unranked

1 citations

Gerald J. Dal Pan

Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000–2020

Drug Safety(2024)10.1007/s40264-024-01443-3

N/A

0DataRank · unranked

6 citations

Ameet Sarpatwari, Krista F. Huybrechts, Joyce Lii, Su Been Lee, Gita A. Toyserkani +6 more

Postmarketing Safety‐Related Regulatory Actions for New Therapeutic Biologics Approved in the United States 2002–2014: Similarities and Differences With New Molecular Entities

Clinical Pharmacology & Therapeutics(2020)10.1002/cpt.1948

N/A

0DataRank · unranked

30 citations

Ellen Pinnow, Brendan Day, Sanae Cherkaoui, Manish Kalaria, Sonja Brajovic +2 more

Response to FDA Adverse Event Reporting System (FAERS) Essentials: A Reflection on Study Conception

Clinical Pharmacology & Therapeutics(2025)10.1002/cpt.70040

N/A

0DataRank · unranked

0 citations

E. Lake Potter, Gerald J. Dal Pan, Melissa Reyes

FDA Adverse Event Reporting System (FAERS) Essentials: A Guide to Understanding, Applying, and Interpreting Adverse Event Data Reported to FAERS

Clinical Pharmacology & Therapeutics(2025)10.1002/cpt.3701

N/A

0DataRank · unranked

86 citations

Melissa Reyes, Jennifer L. Greene-Naples, Gerald J. Dal Pan, E. Lake Potter

Changes in emergency department visits for zolpidem‐attributed adverse drug reactions after FDA Drug Safety Communications

Pharmacoepidemiology and Drug Safety(2020)10.1002/pds.4952

N/A

0DataRank · unranked

7 citations

Esther H. Zhou, Daniel S. Budnitz, Maribeth C. Lovegrove, Gerald J. Dal Pan, Andrew I. Geller

The Impact of Variability in Patient Exposure During Premarket Clinical Development on Postmarket Safety Outcomes

Clinical Pharmacology & Therapeutics(2021)10.1002/cpt.2320

N/A

0DataRank · unranked

7 citations

Ellen Pinnow, Ilynn Bulatao, Brendan Day, Manish Kalaria, Sonja Brajovic +2 more